PTE - PolarityTE, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.9300
-0.1100 (-2.18%)
At close: 4:00PM EDT

4.9300 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close 5.0400
Open 5.1000
Bid 4.9000 x 900
Ask 4.9900 x 4000
Day's Range 4.8500 - 5.1000
52 Week Range 3.8400 - 30.8800
Volume 204,657
Avg. Volume 336,492
Market Cap 123.781M
Beta (3Y Monthly) 1.64
PE Ratio (TTM) N/A
EPS (TTM) -4.7690
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 2016-01-12
1y Target Est 24.71
Trade prices are not sourced from all markets
  • Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%
    Simply Wall St.

    Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%

    PolarityTE, Inc. (NASDAQ:PTE) shareholders should be happy to see the share price up 11% in the last week. But that...

  • PolarityTE Granted Canadian Patent
    PR Newswire

    PolarityTE Granted Canadian Patent

    SALT LAKE CITY , Aug. 20, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that ...

  • PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
    PR Newswire

    PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds

    SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone.

  • PolarityTE Reports Second Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports Second Calendar Quarter 2019 Results

    SALT LAKE CITY , Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019
    PR Newswire

    PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019

    SALT LAKE CITY, July 25, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar second quarter 2019 financial results by press release on Thursday, August 8, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Thursday, August 8, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-394-8218 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 1393700 and referencing "PolarityTE Second Quarter 2019 Earnings Call".  A webcast of the conference call can be accessed by using the link below.

  • PolarityTE Enters Oversold Territory
    Zacks

    PolarityTE Enters Oversold Territory

    PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Is PolarityTE, Inc. (PTE) A Good Stock To Buy ?
    Insider Monkey

    Is PolarityTE, Inc. (PTE) A Good Stock To Buy ?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)?
    Simply Wall St.

    What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)?

    The big shareholder groups in PolarityTE, Inc. (NASDAQ:PTE) have power over the company. Institutions will often hold...

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • Benzinga

    PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

    PolarityTE presented final results from a pilot study on the use of its SkinTE product for hard-to-treat diabetic foot ulcers, or DFUs, as a poster, which showed that 10 of the 11 patients evaluated in the study had healed DFUs within eight weeks of SkinTE application, with a mean time to heal of 29.7 days. SkinTE is an autologous, homologous human cellular and tissue-based product capable of regenerating full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. PolaityTE said the abstract will be published in the online supplement to the journal Diabetes later this year.

  • PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
    PR Newswire

    PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE

    SALT LAKE CITY, June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs). The data was presented at the American Diabetes Association's 79th Scientific Sessions conference. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.

  • Benzinga

    Ready Trader One: Events, Stocks To Watch At E3

    The 24th Electronic Entertainment Expo (E3) kicks off June 11 in Los Angeles, but the news is already flowing this weekend, with many gaming companies showcasing their biggest announcements and presentations. ...

  • PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance
    PR Newswire

    PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance

    SALT LAKE CITY, June 3, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) today announced that the Board of Directors has created the Office of the Chief Executive, consisting of a team of three senior executives who will focus and collaborate on commercialization, operational and financial performance, and new product development. Members of the Office of the Chief Executive include Richard Hague, Chief Operating Officer, Paul Mann, Chief Financial Officer and David Seaburg, President of Corporate Development.  Dr. Denver Lough remains the Chairman of the Board and is on indefinite administrative leave from the offices of Chief Executive Officer and Chief Research & Development Officer.

  • Analysts Recommend These 3 Falling Knives
    GuruFocus.com

    Analysts Recommend These 3 Falling Knives

    The following companies can be considered "falling knives" because their share prices have declined more than 59% over the past 52 weeks through May 30. Wall Street is also optimistic about them as it issued recommendation ratings ranging from overweight to buy with average target prices that produce at least 135% stock appreciation within 52 weeks. Warning! GuruFocus has detected 3 Warning Signs with PTE.

  • Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference
    PR Newswire

    Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference

    SALT LAKE CITY, May 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that final data from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs), will be presented at the American Diabetes Association's 79th Scientific Sessions conference at the Moscone Center in San Francisco, California. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. The poster, Results of a Pilot Evaluation of a Novel Autologous Homologous Skin Construct Treatment of Diabetic Foot Wounds Refractory to Conventional Treatments (#45-LB), will be presented on Sunday, June 9, 2019 from 12:00 PM – 1:00 PM by David G. Armstrong, MD, PhD, DPM, Professor of Clinical Surgery at the Keck School of Medicine at the University of Southern California and co-Director of the Southwestern Academic Limb Salvage Alliance.

  • Implied Volatility Surging for PolarityTE (PTE) Stock Options
    Zacks

    Implied Volatility Surging for PolarityTE (PTE) Stock Options

    PolarityTE (PTE) needs investors to pay close attention to the stock based on moves in the options market lately.

  • 3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
    Zacks

    3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

    So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

  • PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE
    PR Newswire

    PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE

    SALT LAKE CITY, May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today data from two pilot studies on the use of its SkinTE™ product both showing successful closure of diabetic foot ulcers (DFUs) and venous stasis leg ulcers (VLUs) within a 12-week period. The cases involved patients with lower extremity chronic wounds that were difficult to treat or had failed to heal with standard dressing care and conventional treatments, using a single application of SkinTE. The data from each of the clinical case series was presented yesterday at the Symposium on Advanced Wound Care (SAWC) spring conference in San Antonio, TX.

  • PolarityTE Reports First Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports First Calendar Quarter 2019 Results

    SALT LAKE CITY , May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • Should You Be Concerned About PolarityTE, Inc.'s (NASDAQ:PTE) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About PolarityTE, Inc.'s (NASDAQ:PTE) Historical Volatility?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a me...

  • PolarityTE to Report Calendar First Quarter Financial Results on May 10, 2019
    PR Newswire

    PolarityTE to Report Calendar First Quarter Financial Results on May 10, 2019

    SALT LAKE CITY, May 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar first quarter 2019 financial results by press release on May 10, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Friday, May 10, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-800-289-0438 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 3828997 and referencing "PolarityTE First Quarter 2019 Earnings Call."  A webcast of the conference call can be accessed by using the link below.

  • SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting
    PR Newswire

    SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting

    SALT LAKE CITY, April 24, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that new clinical data on the use of its SkinTE™ product will be presented at the Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society meeting in San Antonio, TX from May 7 – 11, 2019. In addition, PolarityTE will host a booth and an interactive event featuring patients treated with SkinTE and a presentation from Dr. Gerhard S. Mundinger, MD, Division of Plastic Surgery, Louisiana State University Health Sciences Center, an early adopter of SkinTE, on his clinical experience with the product.

  • Why PolarityTE Is Sinking Today
    Motley Fool

    Why PolarityTE Is Sinking Today

    Shares drop after the company announces that it is raising capital. Here are the must-know details for investors.

  • PolarityTE Announces Pricing of Public Offering of Common Stock
    PR Newswire

    PolarityTE Announces Pricing of Public Offering of Common Stock

    SALT LAKE CITY, April 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today the pricing of an underwritten public offering of approximately $27.5 million of shares of its common stock. In addition, PolarityTE has granted the underwriter a 30-day option to purchase up to $4,125,000 of additional shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

  • PolarityTE Announces Public Offering of Common Stock
    PR Newswire

    PolarityTE Announces Public Offering of Common Stock

    SALT LAKE CITY, April 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, PolarityTE intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the price to the public, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.